Completed NA INTERVENTIONAL 3-arm NCT01345435

Effects of Telemonitoring and Telemedicine Service for Type 2 Diabetes Care (Smart-DM)

A Multi-center, Randomized, Parallel, Interventional, Open Label Trial to Compare Hemoglobin A1C-lowering Effect of Conventional Treatment and Smart Care Service in Patients With Type 2 Diabetes

Sponsor: CHANGHEE LEE

Conditions Type 2 Diabetes

Interventions SMBG Telemonitoring & Telemedicine Telemonitoring group

Updated 8 times since 2017 Last updated: Feb 1, 2020 Started: Jan 31, 2011 Primary completion: Apr 30, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Type 2 Diabetes, this trial is completed. The trial is conducted by CHANGHEE LEE and has accumulated 8 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed NA
Sep 2024 — Sep 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Oct 2021 — Jul 2024 [monthly]

Completed NA
Jan 2021 — Oct 2021 [monthly]

Completed NA

▶ Show 3 earlier versions

Mar 2020 — Jan 2021 [monthly]

Completed NA
Jun 2018 — Mar 2020 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CHANGHEE LEE
LG Electronics Inc.
Purdue University

Data source: LG Electronics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Daegu, South Korea
• Seoul, South Korea